199 related articles for article (PubMed ID: 26860947)
1. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
2. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract][Full Text] [Related]
3. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
4. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
5. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
6. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
7. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
8. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
9. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC; Moasser MM
Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
[TBL] [Abstract][Full Text] [Related]
11. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
[TBL] [Abstract][Full Text] [Related]
12. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
14. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
[TBL] [Abstract][Full Text] [Related]
16. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
17. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
18. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.
Amin DN; Ahuja D; Yaswen P; Moasser MM
Mol Cancer Ther; 2015 Dec; 14(12):2805-17. PubMed ID: 26438156
[TBL] [Abstract][Full Text] [Related]
19. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
20. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
